Next Article in Journal
Genome-Wide Identification and Expression Analysis of the HD-Zip Gene Family in Wheat (Triticum aestivum L.)
Next Article in Special Issue
Covalent Strategies for Targeting Messenger and Non-Coding RNAs: An Updated Review on siRNA, miRNA and antimiR Conjugates
Previous Article in Journal
Autosomal Recessive NRL Mutations in Patients with Enhanced S-Cone Syndrome
Previous Article in Special Issue
lncRNA Gene Signatures for Prediction of Breast Cancer Intrinsic Subtypes and Prognosis

Long Non-Coding RNAs in Multiple Myeloma

Department of Oncology and Hemato-Oncology, University of Milan, and Hematology, Fondazione Ca’ Granda IRCCS Policlinico, 20122 Milan, Italy
Author to whom correspondence should be addressed.
Genes 2018, 9(2), 69;
Received: 14 December 2017 / Revised: 18 January 2018 / Accepted: 26 January 2018 / Published: 1 February 2018
(This article belongs to the Special Issue Non-coding RNAs)
Multiple myeloma (MM) is an incurable disease caused by the malignant proliferation of bone marrow plasma cells, whose pathogenesis remains largely unknown. Although a large fraction of the genome is actively transcribed, most of the transcripts do not serve as templates for proteins and are referred to as non-coding RNAs (ncRNAs), broadly divided into short and long transcripts on the basis of a 200-nucleotide threshold. Short ncRNAs, especially microRNAs, have crucial roles in virtually all types of cancer, including MM, and have gained importance in cancer diagnosis and prognosis, predicting the response to therapy and, notably, as innovative therapeutic targets. Long ncRNAs (lncRNAs) are a very heterogeneous group, involved in many physiological cellular and genomic processes as well as in carcinogenesis, cancer metastasis, and invasion. LncRNAs are aberrantly expressed in various types of cancers, including hematological malignancies, showing either oncogenic or tumor suppressive functions. However, the mechanisms of the related disease-causing events are not yet revealed in most cases. Besides emerging as key players in cancer initiation and progression, lncRNAs own many interesting features as biomarkers with diagnostic and prognostic importance and, possibly, for their utility in therapeutic terms as druggable molecules. This review focuses on the role of lncRNAs in the pathogenesis of MM and summarizes the recent literature. View Full-Text
Keywords: long non-coding RNAs (lncRNAs); multiple myeloma (MM); expression profiling; transcription regulation long non-coding RNAs (lncRNAs); multiple myeloma (MM); expression profiling; transcription regulation
Show Figures

Figure 1

MDPI and ACS Style

Nobili, L.; Ronchetti, D.; Agnelli, L.; Taiana, E.; Vinci, C.; Neri, A. Long Non-Coding RNAs in Multiple Myeloma. Genes 2018, 9, 69.

AMA Style

Nobili L, Ronchetti D, Agnelli L, Taiana E, Vinci C, Neri A. Long Non-Coding RNAs in Multiple Myeloma. Genes. 2018; 9(2):69.

Chicago/Turabian Style

Nobili, Lucia; Ronchetti, Domenica; Agnelli, Luca; Taiana, Elisa; Vinci, Cristina; Neri, Antonino. 2018. "Long Non-Coding RNAs in Multiple Myeloma" Genes 9, no. 2: 69.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop